PharmaShots Weekly Snapshots (August 30 - September 03, 2021)
Published: Sept 3, 2021 | Tags: Forte, FB-401, P-II, Clinical Trial, Atopic Dermatitis
Novartis Cosentyx (secukinumab) Receives NICE Recommendation for Patients with Plaque Psoriasis
Published: Sept 3, 2021 | Tags: Novartis, Cosentyx, secukinumab, NICE Recommendation, Plaque Psoriasis
Published: Sept 3, 2021 | Tags: Pfizer, P-III, RENOIR trial, RSVpreF Vaccine, Respiratory Syncytial Virus
Published: Sept 3, 2021 | Tags: Alexion, Ultomiris, ravulizumab, EC, Approval, Paroxysmal Nocturnal Haemoglobinuria, EU
Abbott to Acquire Walk Vascular to Bolster its Peripheral Vascular Offerings
Published: Sept 3, 2021 | Tags: Abbott, Walk Vascular, Thrombectomy System, Peripheral Blood Clots
Baxter to Acquire Hillrom for ~$10.5B
Published: Sept 3, 2021 | Tags: Baxter, Acquire, Hillrom, ~$10.5B
Published: Sept 2, 2021 | Tags: Janssen, Invega Hafyera, paliperidone palmitate, US, FDA, Approval, Schizophrenia
Published: Sept 2, 2021 | Tags: Astellas, Dosing, AT132, ASPIRO Clinical Trial, X-linked Myotubular Myopathy
Published: Sept 2, 2021 | Tags: BeiGene, Brukinsa, Zanubrutinib, US, FDA, Approval, Waldenström's Macroglobulinemia
BMS Exercised Its Option to License Evotec's EVT8683 for the Treatment of Neurodegenerative Disease
Published: Sept 2, 2021 | Tags: BMS, Exercised Its Option, License, Evotec, EVT8683
Published: Sept 2, 2021 | Tags: Takeda, Pevonedistat, Azacitidine, P-III, PANTHER Trial, Cancer
Published: Sept 2, 2021 | Tags: AstraZeneca, Thermo Fisher, Co-Develop, NGS-based CDx, Targeted Therapies
Published: Sept 1, 2021 | Tags: Merck, Ridgeback, P-III, MOVe-AHEAD Study, Molnupiravir, COVID-19
Published: Sept 1, 2021 | Tags: Merck, Keytruda, Pembrolizumab, US, FDA, Approval, Urothelial Carcinoma
Johnson & Johnson Discontinues the P-IIb Imbokodo Trial of HIV Vaccine Regimen for HIV Infection
Published: Sept 1, 2021 | Tags: Johnson & Johnson, P-IIb, Imbokodo Trial, HIV Vaccine Regimen, HIV Infection
Published: Sept 1, 2021 | Tags: Bayer, P-III, OASIS Program, Elinzanetant, Vasomotor Symptoms, Menopause
Published: Sept 1, 2021 | Tags: AC Immune, Semorinemab, P-II, Lauriet Study, Alzheimer's Disease
Published: Sept 1, 2021 | Tags: Novartis, NHS, Commercialize, Leqvio, inclisiran, Cardiovascular Disease
Published: Aug 31, 2021 | Tags: Boehringer Ingelheim, Eli Lilly, Jardiance, empagliflozin, P-III, EMPEROR-Preserved Trial, HFpEF ESC 2021
Published: Aug 31, 2021 | Tags: Janssen, Uptravi, selexipag, P-III, GRIPHON, P-IIIb, TRITON Clinical Trials, Pulmonary Arterial Hypertension
Baxter in Talks to Acquire Hill-Rom for ~$10B
Published: Aug 31, 2021 | Tags: Baxter, Acquire, Hill-Rom, ~$10B
Bone Therapeutics's JTA-004 Fails to Meet its All Endpoints in P-III Study for Knee Osteoarthritis
Published: Aug 31, 2021 | Tags: Bone Therapeutics, JTA-004, P-III, Study, Knee Osteoarthritis
GSK and SK Bioscience Initiate P-III Study of GBP510 Against AZ/Oxford's COVID-19 Vaccine
Published: Aug 31, 2021 | Tags: GSK, SK Bioscience, P-III, Study, GBP510, AZ/Oxford's COVID-19 Vaccine
Published: Aug 31, 2021 | Tags: Abbott, Amplatzer Amulet, Boston Scientific, Watchman Device, Atrial Fibrillation, ESC2021
Pfizer Reports Results of Abrocitinib in P-III JADE DARE Study to Treat Atopic Dermatitis
Published: Aug 30, 2021 | Tags: Pfizer, Abrocitinib, P-III, JADE DARE Study, Atopic Dermatitis
SpringWorks Collaborates with Dana-Farber to Evaluate Nirogacestat in Multiple Myeloma
Published: Aug 30, 2021 | Tags: SpringWorks, Dana-Farber, Nirogacestat, Multiple Myeloma
Published: Aug 30, 2021 | Tags: Sanofi, Regeneron, Dupixent, P-III, Study, Atopic Dermatitis
Published: Aug 30, 2021 | Tags: Bio-Thera, Hikma, Exclusive Commercialization, License Agreement, BAT2206, biosimilar, ustekinumab, US
Published: Aug 30, 2021 | Tags: MicroTransponder, US, FDA, Approval, Vivistim System, First Vagus Nerve Stimulation Implant, Stroke Rehabilitation
Published: Aug 30, 2021 | Tags: BeiGene, ImmixBio, IMX-110, Tislelizumab, Solid Tumors
Related Post: PharmaShots Weekly Snapshots (August 23 - 27, 2021)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com